Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Natera, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 11, 2026. Proposals include electing three Class II directors and one Class I director, ratifying Ernst & Young LLP as auditor, and holding advisory votes on executive pay and pay-vote frequency, with the board favoring annual votes.
Stockholders are also asked to approve an amendment to the Amended and Restated 2015 Equity Incentive Plan to add 3,200,000 shares, on top of 4,961,133 shares remaining available and 11,153,080 shares already subject to outstanding awards as of March 31, 2026. The company highlights 2025 performance of $2,306.1 million in total revenue, about 36% growth over 2024, roughly 3.5 million tests processed, and about 800,800 oncology tests, as well as the acquisition of Foresight Diagnostics and over 350 cumulative peer‑reviewed publications supporting its oncology, women’s health, and organ health tests.
Natera, Inc. director and co-founder Jonathan Sheena reported indirect open-market sales of common stock by family trusts associated with him. The trusts sold a total of 1,500 shares on April 17, 2026 in two transactions at weighted average prices of about $199.59 and $199.66 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 7, 2024. The sales were executed by the Caraluna 1 and Caraluna 2 Trusts, which hold the shares for trust beneficiaries, and Sheena disclaims beneficial ownership of those securities. Following these transactions, the filing shows 259,255 Natera shares held directly by Sheena and 20,282 shares reported as held indirectly through each trust.
Natera, Inc. filed an initial insider ownership statement for Eric H. Rubin
Natera, Inc. Executive Chairman Matthew Rabinowitz exercised stock options and used shares to cover taxes. He exercised options to acquire 58,292 shares of Common Stock at an exercise price of $9.59 per share. To satisfy tax obligations, 27,610 shares of Common Stock were withheld at $204.87 per share. Following these transactions, he held 2,383,162 shares of Common Stock directly, plus 5,000 shares held indirectly by his spouse.
Natera, Inc. reported that its Secretary and Chief Legal Officer, Daniel Rabinowitz, conducted open-market sales of company common stock. On April 1, 2026, he sold a total of 8,400 shares at weighted average prices within disclosed ranges between $200.47 and $205.50 per share under a pre-arranged Rule 10b5-1 trading plan. Following these sales, he continued to hold 224,885 shares of Natera common stock directly.
Natera, Inc. executive Solomon Moshkevich reported selling 3,000 shares of Common Stock in open-market transactions. On April 1, 2026, he executed three sales of 1,048, 1,000, and 952 shares at weighted average prices of $201.3206, $202.3638, and $203.3106 per share.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2024, indicating they were scheduled in advance. After these transactions, Moshkevich directly owns 147,882 shares of Natera common stock.
Natera, Inc. Executive Chairman Matthew Rabinowitz exercised stock options to acquire 41,708 shares of Common Stock. He exercised a fully exercisable option with a strike price of $9.59 per share, converting it into 41,708 Common shares on a one-for-one basis.
Following the transaction, he directly holds 2,352,480 shares of Natera Common Stock and 58,292 stock options. In addition, 5,000 Common shares are reported as indirectly owned by his spouse.
Natera, Inc. expanded its Board of Directors from ten to eleven members and appointed Eric Rubin as a Class I director, effective March 26, 2026. His initial term runs until the 2028 annual meeting of stockholders, and the Board has deemed him an independent director under Nasdaq standards.
Dr. Rubin will serve on the Board’s Nominating, Corporate Governance and Compliance Committee and receive cash and equity pay consistent with other non-employee directors under Natera’s Amended Compensation Program for Non-Employee Directors. His initial equity award will vest in three equal installments on March 26, 2027, 2028 and 2029.
The company also entered into an Indemnification Agreement with Dr. Rubin, providing indemnification and advancement of expenses to the fullest extent permitted by law for claims related to his service. There are no family relationships or related-party transactions requiring disclosure in connection with his appointment.
Solomon Moshkevich filed a Form 144 notice indicating planned sales of 3,000 Performance Shares dated 01/14/2026. The filing lists multiple completed common‑share transactions by the same reporting person during early 2026, including a 23,205‑share sale on 01/20/2026 for $5,447,104.57.